Condition
Arginase I Deficiency
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (1)
P 3 (2)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03921541Phase 3CompletedPrimary
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
NCT05676853Phase 3TerminatedPrimary
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
NCT03378531Phase 2CompletedPrimary
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
NCT02488044Phase 1CompletedPrimary
A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
Showing all 4 trials